ewsba.se
Eli Lilly (LLY) has shown revenue growth from a position of strength while Pfizer (PFE) is still rebuilding from the COVID cliff.
For a retirement-focused investor, one may be more temping now but the other may be the stronger long-term franchise.
The analyst who called NVIDIA in 2010 just named his top 10 stocks and Eli Lilly wasn't one of them. Get them here FREE.
Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) recently reported quarterly results that read like two scripts from opposite ends of pharma. Lilly posted 55.55% revenue growth from a position of strength. Pfizer is still rebuilding from the COVID cliff. Their M&A playbooks tell the story.
Lilly's Q1 2026 revenue hit $19.799 billion, adjusted EPS came in at $8.55 against a $6.79 estimate, and management raised full-year revenue guidance to $82.0 billion to $85.0 billion. Mounjaro alone produced $8.662 billion, up 125%, and Zepbound added $4.160 billion. CEO David Ricks framed it bluntly: "2026 is off to a strong start...we also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions."
Pfizer's Q4 2025, by contrast, was a fix-the-foundation quarter. Revenue of $17.56 billion slipped 1.2% year over year, but the non-COVID portfolio grew 9% operationally. Eliquis, Vyndaqel, and Prevnar each posted roughly 10% growth. Comirnaty fell 33% and Paxlovid 70%, exactly the hole Albert Bourla is trying to plug.
Orna, Centessa, Kelonia, Ajax plus $2.75B Insilico AI deal
$7.0B Metsera obesity buy, 3SBio license
Lilly is buying capability from strength: AI drug discovery via Insilico's Pharma.AI platform, plus an Nvidia AI co-innovation lab. Pfizer is buying revenue replacement, having entered obesity only after losing the Metsera bidding battle with Novo Nordisk and discontinuing its own oral GLP-1 danuglipron.
The industry faces 190+ products losing exclusivity and over $300 billion in sales at risk by 2030. Pfizer's own $1.5 billion loss-of-exclusivity hit in 2026 and 2026 EPS guide of $2.80 to $3.00 show the pressure. Vyndamax extension to 2031 and the recent Veppanu approval buy time. Lilly's Foundayo FDA approval, the only anytime oral GLP-1, plus retatrutide Phase 3 wins extend the franchise well past the cliff.
For a retirement-focused investor, the obvious temptation is Pfizer's 6.7% yield and 3.1% year-to-date gain. But on the fundamentals, Lilly screens stronger by a wide margin. Pfizer's M&A is reactive. Lilly's is compounding. Lilly stock is down 11.8% year to date despite a guidance raise, which can be seen as an entry point. Polymarket traders priced a 100% probability of Lilly beating its $7.00 Q1 threshold, and the company delivered $8.55. It is better to pay 34 times earnings for the company writing the next decade's playbook than nine times for one still patching the last one. If Mounjaro pricing in China collapses faster than expected, this may be worth a revisit. Until then, Lilly appears to be the stronger long-term franchise.
This analyst's 2025 picks are up 106% on average. He just named his top 10 stocks to buy in 2026. Get them here FREE.